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naintained a normal TSH during those two to eight
*se Reactions: Adverse reactions, other than those
tive of hyperthyroidism because of therapeutic over, either initially or during the maintenance period are
See OVERDOSAGE).
»instances, allergic skin reactions have been reported
ytomel (liothyronine sodium, SK&F) Tablets.
osage:
and Symptoms—Headache, irritability, nervousness,
tig, tachycardia, increased bowel motility and menirregularities. Angina pectoris or congestive heart
may be induced or aggravated. Shock may also deMassive overdosage may result in symptoms resemhyroid storm. Chronic excessive dosage will produce
ns and symptoms of hyperthyroidism.
tent of Overdosage—Dosage should be reduced or
f temporarily discontinued if signs and symptoms of
jage appear. Treatment may be reinstituted at a
losage. In normal individuals, normal hypothalamicry-thyroid axis function is restored in six to eight
after thyroid suppression.
ent of acute massive thyroid hormone overdosage is
it reducing gastrointestinal absorption of the drugs
interacting central and peripheral effects, mainly
f increased sympathetic activity. Vomiting may be
I initially if further gastrointestinal absorption can
bly be prevented and barring contraindications such
, convulsions, or loss of the gagging reflex. Treatment
tomatic and supportive. Oxygen may be administered
tilation maintained. Cardiac glycosides may be indicongestive heart failure develops. Measures to con*r, hypoglycemia, or fluid loss should be instituted if
Antiadrenergic agents, particularly propranolol,
*en used advantageously in the treatment of insympathetic activity. Propranolol may be administravenously at a dosage of 1 to 3 mg. over a 10-minute
r orally, 80 to 160 mg./day, especially when no conations exist for its use.
and Administration: The dosage of thyroid horB determined by the indication and must in every
individualized according to patient response and
ry findings.
hormones are given orally. In acute, emergency
ns, injectable levothyroxine sodium may be given
ously when oral administration is not feasible or
;, as in the treatment of myxedema coma or during
enteral nutrition j " -stable liothyronine sodium is
lable from Smith Kline &French Laboratories upon
under investigational status, for the treatment of
na coma. Intramuscular administration of these two
ions is not advisable because of reported poor abtomel (liothyronine sodium, SK&F) Tablets oncelage is recommended; although liothyronine sodium
>id cutoff, its metabolic effects persist for a few days
r
discontinuance.
lypothyroidism: Recommended starting dosage is
. daily. Daily dosage then may be increased by 12.5
ncg. every one or two weeks. Usual maintenance
26-75 meg. daily. Smaller doses may be fully effecsome patients, while dosage of 100 meg. daily may
lired in others.
pid onset and dissipation of action of liothyronine
(T3), as compared with levothyroxine sodium (T4),
some clinicians to prefer its use in patients who
>e more susceptible to the untoward effects of thysdication. However, the wide swings in serum T 3
hat follow its administration and the possibility of
ronounced cardiovascular side effects tend to counnce the stated advantages.
1 (liothyronine sodium, SK&F) Tablets may be used
srence to levothyroxine (T4) during radioisotope
Lg procedures, since induction of hypothyroidism in
ises is more abrupt and can be of snorter duration,
also be preferred when impairment of peripheral
ion of T 4 and T 3 is suspected.
ma: Recommended starting dosage is 5 meg.
his may be increased by 5 to 10 meg. daily every
wo weeks. When 25 meg. daily is reached, dosage
*n be increased by 12.5 or 25 meg. every one or two
Jsual maintenance dose is 50 to 100 meg. daily.
ma Coma: Myxedema coma is usually precipithe hypothyroid patient of long standing by interillness or drugs such as sedatives and anesthetics
uld be considered a medical emergency. A 'Cytoection Kit for the emergency treatment of myxoma is available from Smith Kline &French Laboupon request, under investigational status. InIS which accompany this kit provide information
nistration.
tal Hypothyroidism: Recommended starting
5 meg. daily, with a 5 meg. increment every three
ays until the desired response is achieved. Infants
nths old may require only 20 meg. daily for mainAt one year, 50 meg. daily may be required.
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Above three years, full adult dosage may be necessary (See
' PRECAUTIONS, Pediatric Use).
Simple (non-toxic) Goiter: Recommended starting dosage
is 5 meg. daily. This dosage may be increased by 5 to 10
meg. daily every one or two weeks. When 25 meg. daily is
reached, dosage may be increased every week or two by
12.5 or 25 meg. Usual maintenance dosage is 75 meg. daily.
In the elderly or in children, therapy should be started with 5
meg. daily and increased only by 5 meg. increments at the
recommended intervals.
When switching a patient to Cytomel (liothyronine sodium,
SK&F) Tablets from thyroid, L-thyroxine or thyroglobulin,
discontinue the other medication, initiate 'Cytomel' at a low
dosage, and increase gradually according to the patient's
response. When selecting a starting dosage, bear in mind
that this drug has a rapid onset of action, and that residual
effects of the other thyroid preparation may persist for the
first several weeks of therapy.
Thyroid Suppression Therapy: Administration of thyroid
hormone in doses higher than those produced physiologically by the gland results in suppression of the production of
endogenous hormone. This is the basis for the thyroid suppression test and is used as an aid in the diagnosis of patients
with signs of mild hyperthyroidism in whom baseline laboratory tests appear normal or to demonstrate thyroid gland
autonomy in patients with Graves' ophthalmopathy. 131 I
uptake is determined before and after the administration of
the exogenous hormone. A 50 percent or greater suppression
of uptake indicates a normal thyroid-pituitary axis and thus
rules out thyroid gland autonomy.
Cytomel (liothyronine sodium, SK&F) Tablets are given in
doses of 75-100 meg./day for seven days, and radioactive iodine uptake is determined before and after administration of
the hormone. If thyroid function is under normal control, the
radioiodine uptake will drop significantly after treatment.
Cytomel (liothyronine sodium, SK&F) Tablets should be administered cautiously to patients in whom there is a strong
suspicion of thyroid gland autonomy, in view of the fact that
the exogenous hormone effects will be additive to the endogenous source.
How Supplied: Cytomel (liothyronine sodium, SK&F)
tablets: 5 meg. in bottles of 100; 25 meg. in bottles of 100 and
1000; and 50 meg. in bottles of 100.
CY:L30
Shown in Product Identification Section, page 429
D A R B I D ® TABLETS, 5 mg.
[dahr'bid]
(brand of isopropamide iodide)

B

Description: Darbid (brand of isopropamide iodide) is available as a tablet for oral administration. Each round, pink,
coated tablet is imprinted SKF and D62 and contains isopropamide iodide equivalent to 5 mg. of isopropamide. Inactive
ingredients consist of acacia, calcium sulfate, FD&C Red No.
3, FD&C Yellow No. 6, gelatin, iron oxide, mineral oil, starch,
stearic acid, sucrose, talc, titanium dioxide and trace
amounts of other inactive ingredients.
Chemically, Darbid (isopropamide iodide, SK&F) is (3-carbamoyl-3, 3-diphenylpropyl) diisopropylmethyl ammonium iodide.
Actions: Isopropamide iodide is a synthetic anticholinergic
that produces 10- to 12-hour gastric acid antisecretory effect
and gastrointestinal antispasmodic response in man.
Indications: 'Darbid' is effective as adjunctive therapy in
the treatment of peptic ulcer.
'DARBID' HAS NOT BEEN SHOWN TO BE EFFECTIVE
AS SOLE THERAPY IN CONTRIBUTING TO THE HEALr
ING OF PEPTIC ULCER, DECREASING THE RATE OF
RECURRENCE OR PREVENTING COMPLICATIONS.
To be effective, dosage must be titrated to the individual patient's needs.
Contraindications: Glaucoma; obstructive uropathy (e.g.,
bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in acha*:
sia, pyloroduodenal stenosis, etc.); obstructive or paralytic
ileus, intestinal atony of the elderly or debilitated patient;
unstable cardiovascular status in acute hemorrhage; severe
ulcerative colitis; toxic megacolon complicating ulcerative
colitis; myasthenia gravis.
Warnings: In the presence of a high environmental temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur.
In patients with diarrhea due to incomplete intestinal obstruction (especially those with ileostomy or colostomy),
treatment with Darbid (isopropamide iodide, SK&F) would be
inappropriate and possibly harmful.
'Darbid' may produce drowsiness or blurred vision. In this
event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor
vehicle or other machinery or perform hazardous work while
taking this drug.
Usage in Pregnancy: In pregnancy, lactation, and in women
who may bear children, the potential benefits of the drug
must be weighed against possible hazards.

Precautions: Use cautiously in elderly patients.
Since the iodine in isopropamide iodide may alter PBI test
results and will suppress I 131 uptake, it is suggested that
therapy be discontinued one week prior to these tests. Also,
iodine skin rash may^occur rarely.
Use with caution in ^patients with:
Autonomic neuropathy.
Hepatic or renal disease.
Ulcerative colitis Qarge doses may suppress intestinal motility to the point of producing paralytic ileus, and the use of
this drug may precipitate or aggravate the serious complication of toxic megacolon).
Hyperthyroidism, coronary heart disease, congestive heart
failure, cardiac arrhythmia, hypertension and nonobstructing prostatic hypertrophy.
.
'
;•
Hiatal hernia associated with reflux'esophagitis (anticholinergic drugs may aggravate this condition). It should be noted that the use of anticholinergic drugs in the
treatment of gastric ulcer may produce a delay in gastric
emptying time (antral stasis) and, thus, complicate therapy.
Do not rely on the use of the drug in the presence of complication of biliary tract disease.
Investigate any tachycardia before giving anticholinergic
(atropine-like) drugs, since they may increase the heart rate.
With overdosage, a curare-like action may occur.
Adverse Reactions: Anticholinergics produce certain pharmacological effects which may be desirable or undesirable,
depending upon the individual patient's response. The physician must delineate these.
Adverse reactions which have occurred with Darbid (isopropamide iodide, SK&F) include: xerostomia (dry mouth); urinary hesitancy and retention; blurred vision; tachycardia;
palpitations; mydriasis (dilatation of the pupils); cycloplegia;
constipation; bloated feeling; nausea; dysphagia; fever; and
nasal congestion.
Other adverse reactions possible with anticholinergics include: increased ocular tension; loss of taste; headaches; nervousness; drowsiness; weakness; dizziness; insomnia; vomiting; impotence; suppression of lactation; severe allergic reaction or drug idiosyncrasies including anaphylaxis; urticaria
and other dermal manifestations; some degree of mental
confusion and/or excitement, especially in elderly persons.
Decreased sweating may occur. It should be noted that adrenergic innervation of the eccrine sweat glands on the
palms and soles makes complete control of sweating impossible. An end point of complete anhidrosis cannot occur because large dos _ °f drug would be required, and this would
produce severe ^ a e effects from parasympathetic paralysis.
Dosage and Administration: Not for use in children under 12. Adults and children over 12—Usual starting dose is
one 5 mg. tablet b.i.d. (every 12 hours). Patients with severe
symptoms may require two 5 mg. tablets b.i.d., or more. Dosage should be individualized and titrated to the patient's
need for greatest therapeutic effect.
Overdosage: Involves the cardiovascular, respiratory, gastrointestinal, central and peripheral nervous systems.
SYMPTOMS—May include dryness of mouth, dysphagia,
thirst, blurred vision, dilated pupils, photophobia, fever,
rapid pulse and respiration, disorientation. Expression and
circulatory collapse may result from severe overdosage.
TREATMENT—Gastric lavage, repeated several times.
Respiratory depression should be promptly treated by the
use of oxygen and stimulants. If marked excitement is present, one of the short-acting barbiturates, chloral hydrate, or
gas anesthesia may be used. Otherwise do not administer
sedation. Hyperpyrexia may be treated with physical cooling
measures. Force fluids by mouth or, if necessary, by intravenous administration.
While pilocarpine or similar drugs are sometimes recommended for the relief of dry mouth, many authorities feel
that these drugs are not indicated, since they relieve the
minor peripheral effect but do not influence the more serious
central effects and, thus, may merely mask signs of drug
activity. If photophobia occurs, the patient should be kept in
a darkened room.
How Supplied: Tablets, 5 mg., in bottles of 50.
Shown in Product Identification Section, page 429
DB.-L16
DEXEDRINE®
[dex 'eh-dreen ]
(brand of dextroamphetamine sulfate)
SPANSULE® CAPSULES,
TABLETS and ELIXIR

€

Warning:
AMPHETAMINES HAVE A HIGH POTENTIAL FOR
ABUSE. THEY SHOULD THUS BE TRIED ONLY IN
WEIGHT REDUCTION PROGRAMS FOR PATIENTS
IN WHOM ALTERNATIVE THERAPY HAS BEEN
INEFFECTIVE. ADMINISTRATION OF AMPHETAI MINES FOR PROLONGED PERIODS OF TIME IN |
Continued

on next page

Always consult Supplement
* & French—Cont.
{ LEAD TO DRUG DEPENDENCE AND
/OIDED PARTICULAR ATTENTION
PAID TO THE POSSIBILITY OF SUB[NING AMPHETAMINES FOR NON
C USE OR DISTRIBUTION TO OTH
E DRUGS SHOULD BE PRESCRIBED
D SPARINGLY
>xednne (dextroamphetamine sulfate,
ttro isomer of the compound d,l -amphetsympathomimetic amine of the amphet
»mically, dextroamphetamine is d -alpha
imine, and is oresent in all forms of 'Dexeral sulfate
ies
istamed release capsule is so prepared that
eleased promptly and the remaining medi
gradually over a prolonged period
h brown cap and natural body, contains
ne sulfate as follows 5mg imprinted SKF
npnnted SKF and E13,15 mg imprinted
ctive ingredients consist of acacia, benzyl
mlfate, cetylpyndinium chloride, FD&C
Red No 40, FD&C Yellow No 5 (tartra
H[ No 6 gelatin glyceryl distearate, glyc
< sodium lauryl sulfate, starch, sucrose,
uints of other inactive ingredients
an^je, scored tablet is debossed SKF and
xtn^amphetamine sulfate, 5 mg Inactive
of cai^mm sulfate, FD&C Yellow No 5
ifellow **Jo 6, gelatm, lactose, mineral oil,
sucrose, <talc and trace amounts of other
poonful) o-^f clear, orange-colored, orangeains dextroamphetamine sulfate, 5 mg,
Inactive 0 ingredients consist of benzoic
feC Yellovw No 5 (tartrazme), FD&C Yel
icrose, waiter and wine
ology .^Amphetamines are non-catelomimeti^ amines with CNS stimulant
actions include elevations • ystohcand
ures and 'weak bronchodilator and respi
tion
cific e, vidence which clearly establishes
reby aunphetamines produce mental and
i children, nor conclusive evidence reffect^s relate to the condition of the cen
ise^i in obesity are commonly known as
toxigenics " It has not been established,
tion of such drugs m treating obesity is
e tite suppression Other central nervous
netabolic effects, may be involved, for
> instructed in dietary management and
tic ' drugs lose more weight on the aver
ed with placebo and diet, as determined
*rm clinical trials
tcreased weight loss of drug treated pa
reated patients is only a fraction of a
ate of weight loss is greatest m the first
r both drug and placebo subjects and
succeeding weeks The origins of the
»due to the various possible drug effects
The amount of weight loss associated
norectic" drug vanes from trial to trial,
lght loss appears to be related in part to
the drug prescribed, such as the physi
1
population treated, and the diet preDt permit conclusions as to the relative
ig and nondrug factors on weight loss
f obesity is measured in years, whereas
estricted to a few weeks' duration, thus,
ug induced weight loss over that of diet
ered clinically limited
lphetamine sulfate SK&F) Spansule
ed to release the active drug substance
ual fashion than the standard formula
1 by blood levels The formulation has
lor in effectiveness over the same dos
i, noncontrolled release formulations

3mg of dextroamphetamine sulfate in
volunteers produced an average peak
lood level of 33 2 ng /ml The half life
average urinary recovery was 38% in
^estion of two 5 mg tablets by healthy
in average peak dextroamphetamine

blood level of 29 2 ng /ml at 2 hours post administration
The average half life was 10 25 hours The average, unnary
recovery was 45% m 48 hours
'Spansule' capsule—Ingestion of a 'Spansule' capsule con
taming 15 mg radiolabeled dextroamphetamine sulfate by
healthy volunteers produced a peak blood level of radioactiv
lty, on the average, at 8-10 hours post administration with
peak urinary recovery seen at 12-24 hours
Indications a n d Usage Dexednne (dextroamphetamine
sulfate, SK&F) is indicated
1 In Narcolepsy
2 In Attention Deficit Disorder with Hyperactivity, as an
integral part of a total treatment program which typically
includes other remedial measures (psychological, educa
tional, social) for a stabilizing effect in children with a
behavioral syndrome characterized by the following group
of developmentally inappropriate symptoms moderate to
severe distractibihty, short attention span, hyperactivity,
emotional lability, and impulsivity The diagnosis of this
syndrome should not be made with finality when these
symptoms are only of comparatively recent origin Nonlocalizmg (soft) neurological signs, learning disability, and
abnormal EEG may or may not be present, and a diagnosis
of central nervous system dysfunction may or may not be
warranted
3 In Exogenous Obesity, as a short term (a few weeks) ad
junct in a regimen of weight reduction based on caloric
restriction, for patients refractory to alternative therapy,
e g , repeated diets, group programs, and other drugs The
limited usefulness of amphetamines (see CLINICAL
PHARMACOLOGY) should be weighed against possible
risks inherent in use of the drug, such as those described
below
Contraindications Advanced artenosclerosis, symptomatic cardiovascular disease, moderate to severe hyperten
sion, hyperthyroidism, known hypersensitivity or ldiosyn
crasy to the sympathomimetic amines, glaucoma
Agitated states
Patients with a history of drug abuse
During or withm 14 days following the administration of
monoamine oxidase inhibitors (hypertensive crises may result)
Warning When tolerance to the "anorectic" effect devel
ops, the recommended dose should not be exceeded in an
attempt to increase the effect, rather, the drug should be
discontinued
Precautions
General Caution is to be exercised in prescribing ampheta
mine ^ patients with even mild hypertension
The least amount feasible should be prescribed or dispensed
at one time in order to minimize the possibility of overdos
age
These products contain FD&C Yellow # 5 (tartrazme), which
may cause allergic type reactions (including bronchial
asthma) m certain susceptible individuals Although the
overall incidence of FD&C Yellow # 5 (tartrazme) sensitivity
m the general population is low, it is frequently seen m pa
tients who a\so have aspirin hypersensitivity
Information for Patients Amphetamines may impair the
ability of the patient to engage m potentially hazardous ac
tivities such as operating machinery or vehicles, the patient
should therefore be cautioned accordingly
Drug Interactions
Acidifying agents—Gastrointestinal acidifying agents (gua
nethidme, reserpine, glutamic acid HC1, ascorbic acid, fruit
juices, etc) lower absorption of amphetamines Unnary
acidifying agents (ammonium chloride, sodium acid
phosphate, etc) increase the concentration of the ionized
species of the amphetamine molecule, thereby increasing
urinary excretion Both groups of agents lower blood levels
and efficacy of amphetamines
Adrenergic blockers—Adrenergic blockers are inhibited by
amphetamines
Alkalinizmg agents—Gastrointestinal alkalinizmg agents
(sodium bicarbonate, etc) increase absorption of ampheta
mines Urinary alkalinizmg agents (acetazolamide some
thiazides) increase the concentration of the non ionized species of the amphetamine molecule, thereby decreasing u n
nary excretion Both groups of agents increase blood levels
and therefore potentiate the actions of amphetamines
Antidepressants, tricyclic—Amphetamines may enhance
the activity of tricyclic or sympathomimetic agents d
amphetamine with desipramine or protnptylme and possi
bly other tricyclics cause striking and sustained increases in
the concentration of d amphetamine in the bram, cardiovas
cular effects can be potentiated
MAO inhibitors—MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism This
slowing potentiates amphetamines, increasing their effect
on the release of norepinephrine and other monoamines
from adrenergic nerve endings this can cause headaches
and other signs of hypertensive crisis A variety of neurologi
cal toxic effects and malignant hyperpyrexia can occur,
sometimes with fatal results
Antihistamines—Amphetamines may counteract the seda
tive effect of antihistamines

Antihypertensives—Amphetamines may antagonize ^ e
hypotensive effects of antihypertensives
Chlorpromazme—Chlorpromazine blocks dopamine and
norepinephrine reuptake, thus inhibiting the central stim u
lant effects of amphetamines, and can be used to treat am
phetamme poisoning
Ethosuximide—Amphetamines may delay intestinal absom.
tion of ethosuximide
Halopendol—Halopendol blocks dopamine and norepmeph
rine reuptake, thus inhibiting the central stimulant effects
of amphetamines
Lithium carbonate—The antiobesity and stimulatory effects
of amphetamines may be inhibited by lithium carbonate 4
Meperidine—Amphetamines potentiate the analgesic effect
of mependine
Methenamine therapy—Urinary excretion of ampheta
mines is increased, and efficacy is reduced, by acidifying
agents used in methenamine therapy
i
Norepinephrine—Amphetamines enhance the adrenergic
effect of norepinephrine
Phenobarbital—Amphetamines may delay intestinal absorption of phenobarbital, co-administration of phenobarbi
tal may produce a synergistic anticonvulsant action
Phenytom—Amphetamines may delay intestinal absorption
of phenytom, co-administration of phenytom may produce a
synergistic anticonvulsant action
Propoxyphene—In cases of propoxyphene overdosage, am
phetamme CNS stimulation is potentiated and fatal convul
sions can occur
Veratrum alkaloids—Amphetamines inhibit the hypoten
sive effect of veratrum alkaloids
,
Drug/Laboratory Test Interactions
* ^
• Amphetamines can cause a significant elevation m
plasma corticosteroid levels This increase is greatest in
the evening
• Amphetamines may interfere with urinary steroid deter
mmations
Carcinogenesis/Mutagenesis Mutagenicity studies and
long term studies in animals to determine the carcinogenic
potential of Dexednne (dextroamphetamine sulfate, SK&F^
have not been performed
Pregnancy—Teratogenic Effects Pregnancy Category C
'Dexednne' has been shown to have embryotoxic and teratogenic effects when administered to A/Jax mice and C57BL
mice in doses approximately 41 times the maximum human
dose Embryotoxic effects were nr seen m New Zealand
white rabbits given the drug m dose^ / times the human dose
nor in rats given 12 5 times the maximum human dofThere are no adequate and well-controlled studies in preg
nant women 'Dexednne' should be used during pregnancy
only if the potential benefit justifies the potential risk to the
fetus
t
Nonteratogenic Effects Infants born to mothers dependent
on amphetamines have an mcreased risk of premature dehv
ery and low birth weight Also, these infants may expenence
symptoms of withdrawal as demonstrated by dysphoria, in
eluding agitation, and significant lassitude
,
Nursing Mothers It is not known whether this drug is excreted in breast milk, efforts to measure amphetamines in
breast milk have been unsuccessful Because many drugs are
excreted in human milk, caution should be exercised when
Dexednne' is administered to a nursing woman
Pediatric Use Long term effects of amphetamines in chil
dren have not been well established
Amphetamines are not recommended for use as anorectic
agents in children under 12 years of age, or m children under
3 years of age with Attention Deficit Disorder with Hyperac
t m t y described under INDICATIONS AND USAGE
Clinical experience suggests that in psychotic children, ad
ministration of amphetamines may exacerbate symptoms of
behavior disturbance and thought disorder
Amphetamines have been reported to exacerbate motor and
phonic tics and Tourette's syndrome Therefore, clinical
evaluation for tics and Tourette's syndrome in children and
their families should precede use of stimulant medications
Data are inadequate to determine wb *Her chronic adminis
tration of amphetamines may be associated with growth
inhibition therefore, growth should be monitored during
treatment
Drug treatment is not indicated in all cases of Attention Def
lcit Disorder with Hyperactivity and should be considered
only in light of the complete history and evaluation of the
child The decision to prescribe amphetamines should depend on the physician's assessment of the chromcity and
severity of the child's symptoms and their appropriateness
for his/her age Prescription should not depend solely on the
presence of one or more of the behavioral characteristics
When these symptoms are associated with acute stress reac
tions treatment with amphetamines is usually not indi
cated
Adverse Reactions
Cardiovascular Palpitations, tachycardia elevation of
blood pressure
Central Nervous System Psychotic episodes at recom
mended doses (rare), overstimulation, restlessness, dizziness,
insomnia euphoria, dyskinesia, dysphoria, tremor, head

Product Information

possible revisions \B v'f> exacerbation of motor and phonic tics~and Tourette's
J 01 n'estmal ' Dryness of the mouth unpleasant taste,
hea constipation other gastrointestinal disturbances
eX ia and weight loss may occur as undesirable effects
i amphetamines are used for other than the anorectic
t.
gic Urticaria u
Impotence, changes in libido
c r ( ne
r Abuse and Dependence Dextroamphetamine sul
's a Schedule II controlled substance
r
hetammes have been extensively abused Tolerance,
me psychological dependence and severe social disabil
ave occurred There are reports of patients who have
ased the dosage to many times that recommended
pt cessation following prolonged high dosage admims
n results in extreme fatigue and mental depression,
es are also noted on the sleep EEG
Testations of chronic intoxication with amphetamines
le severe dermatoses marked insomnia, irritability,
actiuty, and personality changes The most severe
estation of chronic intoxication is psychosis often clin
indistinguishable from schizophrenia This is rare
)ral amphetamines
"" * A
losage Individual patient response to ampheta
vanes widely While toxic symptoms occasionally oc
an idiosyncrasy at doses as low as 2 m g , they are rare
loses of less than 15 m g , 30 mg can produce severe
)ns, yet doses of 400 to 500 mg are not necessarily fa
,, the oral LDso of dextroamphetamine sulfate is 96 8
I
TOMS—Manifestations of acute overdosage with am
nines include restlessness, tremor, hyperreflexia,
espiration, confusion, assaultiveness, hallucinations,
states
e and depression usually follow the central stimula
vascular effects include arrhythmias, hypertension or
nbion and circulatory collapse Gastrointestinal
>ms include nausea vomiting, diarrhea and abdoi
imps Fatal poisoning is usually preceded by convul
nd coma
IMENT—Management of acute amphetamine intoxi
is largely symptomatic and includes gastric lavage
lation with a barbiturate Experience with hemodialy
entoneal dialysis is inadequate to permit recommen
in this regard Acidification of the urine increases
tamine excretion If acute, severe hypertension com
> amphetamine overdosage, administration of intra
phentolamine (Regitine®, CIBA) has been sug
However, a gradual drop in blood pressure will usu
ult when sufficient sedation has been achieved
oraazme antagonizes the central stimulant effects of
amines and can be used to treat amphetamine intoxi
uch of the Spansule' capsule medication is coated for
release therapy directed at reversing the effects of
*sted drug and at supporting the patient should be
ed for as long as overdosage symptoms remain Sa
hartics are useful for hastening the evacuation of
hat have not already released medication
a n d Administration Regardless of indication,
amines should be administered at the lowest effec
ige and dosage should be individually adjusted Late
doses—particularly with the Spansule' capsule
hould be avoided because of the resulting insomnia
Dsy Usual dose 5 to 60 milligrams per day in di
ses depending on the individual patient response
3sy seldom occurs m children under 12 years of age
, when it does Dexednne (ccxtroamphetamine su
&F) may be used The suggested initial dose for pa
ed 6-12 is 5 mg daily daily dose may be raised in
its of 5 mg at weekly intervals until optimal reobtained In patients 12 years of age and older start
ng daily daily dosage may be raised in increments
at weekly intervals until optimal response is obf bothersome adverse reactions appear (e g msom
lorexia) dosage should be reduced Spansule cap> be used for once-a-day dosage wherever appropn
tablets or elixir give first dose on awakening addi
ses (1 or 2) at intervals of 4 to 6 hours
i Deficit Disorder w i t h Hyperactivity

Not recom

or children under 3 years of age
n f r o m 3 to 5 years of age start w i t h 2 5 mg daily

or elixir daily dosage may be raised in increments
at weekly intervals until optimal response is obn 6 years of age and older start with 5 mg once or
lv daily dosage may be raised in increments of 5
ekly intervals until optimal response is obtained
are cases will it be necessary to exceed a total of 40
is per day

Witli* tablets or elixir, give first dose on awakening "addi
consideration"' In^cases of rmld overdosage, recumbent jpo
tional doses (1 or 2) at intefvals*of 4 to 6 hours ir*jp_s2oq;
tion with legs elevated usually res'tores'cerebral circulatic
Where possible, drug administration should be interrupted
In'the more severe cases the usual measures to comb
occasionally to determine if there is a recurrence of behav j shock should be instituted Usual pressor agents are not
loral symptoms sufficient to require continued therapy •**»
fective Epinephrine is contramdicated because it stimulat
Exogenous Obesity Usual dosage is one 10 or 15 mg 'Span
both a and y3 receptors, since a receptors are blocked, the n
sule' capsule daily, taken in the morning, or up to 30 mg
effect of epinephrine administration is vasodilation and
daily by tablets or elixir, taken in divided doses of 5 to 10 mg
further drop in blood pressure (epinephrine reversal)
30 to 60 minutes before meals Not recommended for this use
The patient may have to be kept flat for 24 hours or more
i
in children under 12 years of age
the case of overdose! as the effect of the drug is"prolonge
How Supplied
Leg band&ges and an abdominal binder may shorten tl
period of disability *
*' iX
'Spansule' capsules available 5 m g , m bottles of 50,10 mg
and 15 m g , in bottles of 50 and 500
I V infusion of levarterenol bitartrate *v may be used to cor.
Tablets, 5 m g , available in bottles of 100 and 1000
bat severe hypotensive reactions, because it stimulates
Elixir, 5 mg /5 ml, available in 16 fl oz (473 m l ) bottles
receptors pnmaril} Although Dibenzyline (phenoxybenz
T
Shown m Product Identification Section, page 429 >
mine hydrochloride, SK&F) is an a adrenergic blocking agen
a sufficient dose of levarterenol bitartrate will overcome th
DXL34
v
effect
How Supplied Dibenzyline (phenoxybenzamine hydr
D I B E N Z Y L I N E ® Capsules
&
chloride, SK&F) capsules, 10 mg, in bottles of 100
[di benz 'eh leen ]
(brand of phenoxybenzamine

hydrochloride)

Description Each 'Dibenzyline' capsule, with red cap and
red body, is imprinted SKF and E33 and contains phenoxy
benzamme hydrochloride, 10 mg Inactive ingredients con
sist of benzyl alcohol, cetylpyndmmm chloride D&C Red No
33, FD&C Red No 3, FD&C Yellow No 6, gelatin, lactose,
sodium lauryl sulfate and trace amounts of other inactive
ingredients
f
>•
^
*
'Dibenzyline'
is
N-<2-Chloroethyl)-N-{l methyl 2
phenoxyethyl) benzylamine hydrochloride
Phenoxybenzamine hydrochloride is a colorless, crystalline
powder with a molecular weight of 340 3 which melts between 136* and 141*C It is soluble in water, alcohol and chloroform, insoluble in ether
Actions Dibenzyline (phenoxybenzamine hydrochloride,
SK&F) is a long acting adrenergic, a receptor blocking agent
which can produce and maintain "chemical sympathec
tomy" by oral administration It increases blood flow to the
skin, mucosa and abdominal viscera, and lowers both supme
a n d e *_ *t blood pressures It has no effect on the parasympa
thetic &ystem
">
Indication Pb^^hromoc}*^ na, to control episodes of
hypertension a n ! oweating If tachycardia is excessive, it
may be necessary to use a beta blocking agent concomi
tantly
Contraindications Conditions where a fall in blood pres
sure may be undesirable
W a r n i n g 'Dibenzyline' induced alpha adrenergic blockade
leaves beta adrenergic receptors unopposed
Compounds
t h a t stimulate both types of receptors may therefore produce
an exaggerated hypotensive response and tachycardia
Precautions
Phenoxybenzamine
hydrochloride
has
s h o w n in vitro mutagenic a c t i v i t y in the Ames test and in
the mouse lymphoma assay it has not shown mutagenic
a c t i v i t y in the micronucleus test in mice In rats and mice
repeated intraperitoneal administration of phenoxybenza
mine hydrochloride resulted in peritoneal sarcomas Chronic
oral dosing in rats has produced malignant t u m o r s of t h e
gastrointestinal tract
'
The clinical significance of such test results is not established Nevertheless these results should be given consider
ation in determining the benefit risk ratio as it applies t o the
individual patient
Administer w i t h caution in patients w i t h marked cerebral or
coronary arteriosclerosis or renal damage Adrenergic block
ing effect may aggravate symptoms of respiratory infections

Adverse Reactions Nasal congestion miosis postural hy
potension tachycardia and inhibition of ejaculation may
occur rt ru se so-called ' side effects" are actually evidence of
adrenergic blockade and vary according to the degree of
blockade Furthermore they tend to decrease as therapy is
continued Gastrointestinal irritation drowsiness and fa
tigue have also been reported
Dosage and Administration The dosage should be ad
justed to fit the needs of each patient Small initial doses
should be slowly increased until the desired effect is obtained
or the side effects from blockade become troublesome After
each increase the patient should be observed on that level be
fore instituting another increase The dosage should be car
ned to a point where symptomatic relief and/or objective
improvement are obtained but not so high that the side ef
fects from blockade become troublesome
Initially 10 mg of Dibenzyline (phenoxybenzamine hydrochloride SK&F) twice a day Dosage should be increased every
other day usually to 20 to 40 mg two or three times a da>
until an optimal dosage is obtained as judged by blood pres
sure control
Overdosage Symptoms—These are largely the result of
block of the sympathetic nervous system and of the circulat
ing epinephrine They may include postural hypotension
resulting in dizziness or fainting tachycardia particularly
postural vomiting lethargy shock Treatment —When

*Ayailable as Levophed® Bitartrate (brand of levarterent
bitartrate) from Wmthrop Laboratories
Shown in Product Identification Section, page 429
DIL2
DYAZIDE®

Capsules

[dye uh zide' ]
('Dyazide' is a product of SK&F Co, Carolina, P R 0063C
Subsidiary
of
SmithKline
Beckman
Corporation
Philadelphia, Pa)
Warning
This fixed combination drug is not indicated for initial
therapy of edema or hypertension Edema or hyperten
sion requires therapy titrated to the individual patient
If the fixed combination represents the dosage so deter
mined, its use may be more convenient in patient man
agement The treatment of hypertension and edema i£
not static, but must be reevaluated as c o i t i o n s m
each patient warrant
Description Each red and v*hite 'Dyazide' capsule con
tains 50 mg of Dyremum® (brand of triamterene), a potassi
um-sparing agent, and 25 mg of hydrochlorothiazide
'Dyremum' is 2, 4, 7 tnamino-6-phenylpteridine
Hydrochlorothiazide is 6-chloro-3, 4-dihydro-2H 1, 2 , 4 ben
zothiadiazine-7-sulfonamide 1,1 -dioxide
At 50*C, triamterene is practically insoluble in water (less
than 0 1%) It is soluble in formic acid, spanngly soluble in
methoxyethanol, and very slightly soluble in alcohol
Hydrochlorothiazide is slightly soluble m water It is soluble
in dilute ammonia, dilute aqueous sodium hydroxide, and
dimethylformamide It is sparingly soluble in methanol
Action 'Dyazide is a diuretic/antihypertensive drug prod
uct that combines the natriuretic hydrochlorothiazide, and
the potassium sparing natnuretic, triamterene, each of
which complements the action of the other The hydrochlorothiazide component blocks the reabsorption of sodium and
chloride ions, and thereby increases the quantity of sodium
traversing the distal tubule and the volume of water ex
creted A portion of the additional sodium presented to the
distal tubule is exchanged there for potassium and hydrogen
ions With continued use of hydrochlorothiazide and depletion of sodium, compensatory mechanisms tend to increase
this exchange and may produce excessive loss of potassium,
hydrogen and chloride ions Hydrochlorothiazide also decreases the excretion of calcium and uric acid, may increase
the excretion of iodide and may reduce g l o m e r u l i filtratiou
rate The exact mechanism of the antihyperteruT ""<{ effect of
hydrochlorothiazide is not known
The triamterene component of Dyazide' exerts its diuretic
effect on the distal renal tubule to inhibit the reabsorption of
sodium in exchange for potassium and hydrogen ions Its
natriuretic activity is limited by the amount of sodium
reaching its site of action Although it blocks the increase in
this exchange that is stimulated by mmeralocorticoids
(chiefly aldosterone) it is not a competitive antagonist of al
dosterone and its activity can be demonstrated m adrenalec
tomized rats and patients with Addison s disease As a result
the dose of triamterene required is not proportionally related to the level of mmeralocorticoid activity but is dictated
by the response of the individual patient and the kaliuretic
effect of concomitantly administered drugs By inhibiting
the distal tubular exchange mechanism triamterene main
tains or increases the sodium excretion and reduces the ex
cess loss of potassium hydrogen and chloride ions induced
by hydrochlorothiazide As with hydrochlorothiazide
triamterene may reduce glomerular filtration and renal
plasma flow Via this mechanism it may reduce uric acid
excretion although it has no tubular effect on uric acid reabsorption or secretion Triamterene does not affect calcium ^

organism is not likely to be eradicated from the nanx of asymptomatic carriers
vpplied Capsules, 300 mg (opaque scarlet and cara
ttles of 30, 60, and 100 Also available, Rimac
[NH (isoniazid USP) Dual Pack containing 60 Rimacpsules and 30 INH 300-mg Tablets
ice
5r, A W , Kirby, W M M , Sherns, J C, and Turck,
miotic susceptibility testing by a standardized single
thod Am J Clin Path 45 493-496, 1966
C83-8 (Rev 7/83)
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ihenidate hydrochloride USP)
IIM-SR®
ihenidate hydrochloride)
d release tablets

G

tion- Ritalin is a white, odorless, fine crystalline
solutions of which are acid to litmus It is freely soluater
Pharmacology: Ritalin is a mild central nervous
timulant
e of action in man is not completely understood, but
>resumably activates the brain stem arousal system
ex to produce its stimulant effect
neither specific evidence which clearly establishes
hanism whereby Ritalin produces its mental and
al effects in children, nor conclusive evidence rehow these effects relate to the condition of the cens u s system
n the SR tablets is more slowly but as extensively
1 as in the regular tablets Relative bioavailability of
ablet compared to the Ritalin tablet, measured by
ary excretion of Ritalin major metabolite (a phenyl
line acetic acid) was 105% (49-168%) in children
Vo (85-152%) in adults The time to peak rate in chil
> 4 7 hours (13-8 2 hours) for the SR tablets and 1 9
3-4 4 hours) for the tablets An average of 67% of SR
>se was excreted in children as compared to 86% m
n Deficit Disorder Narcolepsy (previously known
nal Brain Dysfunction in Children) Other terms
ed to describe the behavioral syndromf ^ low in
yperkmetic Child Syndrome, Minimal Biain Damumal Cerebral Dysfunction, Minor Cerebral Dyss indicated as an integral part of a total treatment
which typically includes other remedial measures
)gical, educational, social) for a stabilizing effect in
with a behavioral syndrome characterized by the
I group of developmental^ inappropriate symploderate-to-severe distractibihty, short attention
peractivity, emotional lability, and impulsivity The
s of this syndrome should not be made with finality
Bse symptoms are only of comparatively recent on
localizing (soft) neurological signs, learning disabilabnormal EEG may or may not be present, and a
s of central nervous system dysfunction may or may
arranted
diagnostic Considerations
etiology of this syndrome is unknown, and there is
diagnostic test Adequate diagnosis requires the use
of medical but of special psychological, educational,
il resources
nstics commonly reported include chronic history
attention span, distractibihty, emotional lability,
ity, and moderate-to-severe hyperactivity, minor
ical signs and abnormal EEG Learning may or may
i paired The diagnosis must be based upon a com
-ory and evaluation of the child and not solely on the
of one or more o r *hese characteristics
atment is not inaicdted for all children with this
B Stimulants are not intended for use in the child
bits symptoms secondary to environmental factors
nmary psychiatric disorders, including psychosis
ate educational placement is essential and psychoervention is generally necessary When remedial
> alone are insufficient, the decision to prescribe
t medication will depend upon the physician's as
of the chronicity and severity of the child's sympldications' Marked anxiety, tension, and agita
contraindications to Ritalin, since the drug may
e these symptoms Ritalin is contramdicated also in
known to be hypersensitive to the drug, in patients
coma, and in patients with motor tics or with a fam
y or diagnosis of Tourette's syndrome
s Ritalin should not be used in children under six
ice safety and efficacy in this age group have not
bhshed

Sufficient data on safety and efficacy of long term use of Ritalin in children are not yet available Although a causal relationship has not been established, suppression of growth (le,
weight gain, and/or height) has been reported with the longterm use of stimulants in children Therefore, patients requiring long term therapy should be carefully monitored
Ritalin should not be used for severe depression of either
exogenous or endogenous origin Clinical experience suggests that in psychotic children, administration of Ritalin
may exacerbate symptoms of behavior disturbance and
thought disorder
Ritalin should not be used for the prevention or treatment of
normal fatigue states
There is some clinical evidence that Ritalin may lower the
convulsive threshold in patients with prior history of seizures, with prior EEG abnormalities in absence of seizures,
and, very rarely, in absence of history of seizures and no
prior EEG evidence of seizures Safe concomitant use of anti
convulsants and Ritalin has not been established In the
presence of seizures, the drug should be discontinued
Use cautiously in patients with hypertension Blood pressure
should be monitored at appropriate intervals in all patients
taking Ritalin, especially those with hypertension
Symptoms of visual disturbances have been encountered in
rare cases Difficulties with accommodation and blurring of
vision have been reported
Drug Interactions
Ritalin may decrease the hypotensive effect of guanethidine
Use cautiously with pressor agents and MAO inhibitors
Human pharmacologic studies have shown that Ritalin may
inhibit the metabolism of coumann anticoagulants, anticon
vulsants (phenobarbital, diphenylhydantom, primidone),
phenylbutazone, and tricyclic antidepressants (lmipramine,
desipramme) Downward dosage adjustments of these drugs
may be required when given concomitantly with Ritalin
Usage in Pregnancy
Adequate animal reproduction studies to establish safe use
of Ritalin during pregnancy have not been conducted Therefore, until more information is available, Ritalin should not
be prescribed for women of childbearmg age unless, in the
opinion of the physician, the potential benefits outweigh the
possible risks
Drug Dependence

Ritalin should be given cautiously to emotionally unsta
ble patients, such as those with a history of drug depen
dence or alcoholism, because such patients may in
crease dosage on their own initiative
Chronically abusive use can lead to marked tolerance
and psychic dependence with varying degrees of abnor
mal behavior Frank psychotic episodes can occur, espe
cially with parenteral abuse Careful supervision is required during drug withdrawal, since severe depression
as well as the effects of chronic overactivity can be un
masked Long term follow up may be required because
of the patient's basic personality disturbances
Precautions: Patients with an element of agitation may
react adversely, discontinue therapy if necessary
Periodic CBC, differential, and platelet counts are advised
during prolonged therapy
Drug treatment is not indicated in all cases of this behavioral
syndrome and should be considered only in light of the com
plete history and evaluation of the child The decision to prescribe Ritalin should depend on the physician's assessment
of the chronicity and severity of the child's symptoms and
their appropriateness for his/her age Prescription should
not depend solely on the presence of one or more of the be
havioral characteristics
When these symptoms are associated with acute stress reac
tions, treatment with Ritalin is usually not indicated
Long term effects of Ritalin in children have not been well
established
Adverse Reactions* Nervousness and insomnia are the
most common adverse reactions but are usually controlled
by reducing dosage and omitting the drug in the afternoon or
evening Other reactions include hypersensitivity (including
skin rash, urticaria, fever, arthralgia, exfoliative dermatitis,
erythema multiforme with histopathological findings of
necrotizing vasculitis, and thrombocytopenic purpura), anorexia, nausea, dizziness, palpitations, headache, dyskinesia,
drowsiness, blood pressure and pulse changes, both up and
down, tachycardia, angina, cardiac arrhythmia, abdominal
pain, weight loss during prolonged therapy There have
been rare reports of Tourette's syndrome Toxic psychosis
has been reported Although a definite causal relationship
has not been established, the following have been reported in
patients taking this drug leukopenia and/or anemia, a few
instances of scalp hair loss
In children, loss of appetite, abdominal pain, weight loss
during prolonged therapy, insomnia, and tachycardia may
occur more frequently, however, any of the other adverse
reactions listed above may also occur
Dosage and Administration Dosage should be individu
ahzed according to the needs and responses of the patient

Adults

Tablets Administer m divided doses 2 or 3 times daily,
preferably 30 to 45 minutes before meals Average dosage is
20 to 30 mg daily Some patients may require 40 to 60 mg
daily In others, 10 to 15 mg daily will be adequate Patients
who are unable to sleep if medication is taken late in the day
should take the last dose before 6 p m
SR Tablets Ritalin SR Tablets have a duration of action of
approximately 8 hours Therefore, Ritalin SR tablets may be
used m place of Ritalin tablets when the 8 hour dosage of
Ritalin SR corresponds to the titrated 8 hour dosage of Ritalin
Children (6 years and over)

Ritalin should be initiated in small doses, with gradual
weekly increments Daily dosage above 60 mg is not recommended
If improvement is not observed after appropriate dosage
adjustments over a one-month period, the drug should be
discontinued
Tablets Start with 5 mg twice daily (before breakfast and
lunch) with gradual increments of 5 to 10 mg weekly
SR Tablets Ritalin SR tablets have a duration of action of
approximately 8 hours Therefore, Ritalin SR tablets may be
used m place of Ritalin tablets when the 8 hour dosage of
Ritalin SR corresponds to the titrated 8 hour dosage of Ritalin
If paradoxical aggravation of symptoms or other adverse
effects occur, reduce dosage, or, unnecessary, discontinue the
drug
Ritalin should be periodically discontinued to assess the
child's condition Improvement may be sustained when the
drug is either temporarily or permanently discontinued
Drug treatment should not and need not be indefinite and
usually may be discontinued after puberty
Overdosage Signs and symptoms of acute overdosage,
resulting principally from overstimulation of the central
nervous system and from excessive sympathomimetic effects, may include the following- vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be
followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations v-irdiac arrhythmias, hypertension, mydriasis, and dryness of mucous membrane*1
Treatment consists of appropriate suppv * /e measures The
patient must be protected against self injury and against
external stimuli that would aggravate overstimulation already present If signs and symptoms are not too severe and
the patient is conscious, gastric contents may be evacuated
by induction of emesis or gastnc lavage In the presence of
severe intoxication, use a carefully titrated dosage of a short
acting barbiturate before performing gastric lavage
Intensive care must be provided to maintain adequate circulation and respiratory exchange, external cooling procedures may be required for hyperpyrexia
Efficacy of peritoneal dialysis or extracorporeal hemodialysis for Ritalin overdosage has not been established
How Supplied
Tablets 20 mg—round, pale yellow, scored (imprinted CIBA
34)
Bottles of 100
NDC 0083-0034 30
Bottles of 1000
NDC 0083-0034-40
Tablets 10 mg —round, pale green, scored (imprinted CIBA
3)
Bottles of 100
NDC 0083-0003 30
Bottles of 500
NDC 0083-0003-35
Bottles of 1000
NDC 0083-0003-40
Accu Pak® Unit Dose (blister pack)
Box of 100 (strips of 10)
NDC 0083-0003-32
Tablets 5 mg—r™'nd, yellow (imprinted CIBA 7)
Bottles of 100
NDC 0083-0007-30
Bottles of 500
NDC 0083-0007-35
Bottles of 1000
NDC 0083-0007-40
SR Tablets 20 mg—round, white, coated (imprinted CIBA
16)
Bottles of 100
NDC 0083-0016-30
Note SR Tablets are color additive free
Do not store above 86°F (30°C) Protect from moisture
Dispense in tight, light resistant container (USP)
C84-29 (Rev 6/84)
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Continued on next page
The full prescribing information for each CIBA drug is
contained herein and is that in effect as of September 1,
1985

